UBS Group
RPRX icon

UBS Group’s Royalty Pharma RPRX Stock Holding History

UBS Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,800
Closed -$1.16M – 11072
2025
Q3 		$1.16M Hold
32,800
– – ﹤0.01% 5441
2025
Q2 		$1.18M Hold
32,800
– – ﹤0.01% 5297
2025
Q1 		$1.02M Sell
32,800
-17,200
-34% -$545K ﹤0.01% 5274
2024
Q4 		$1.28M Buy
+50,000
New +$1.33M ﹤0.01% 5126
2021
Q3 		– Sell
-150,000
Closed -$6.15M – 9997
2021
Q2 		$6.15M Buy
+150,000
New +$6.38M ﹤0.01% 2474

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

UBS Group's RPRX Position: Q1 2026 in Review

UBS Group reduced its Royalty Pharma (RPRX) stake by 9.7% in Q1 2026, selling an estimated $8.48M and leaving 1,812,203 shares worth $86.9M. The position accounts for 0.01% of the portfolio, ranked #1158.

UBS Group first reported a position in RPRX in Q2 2020 and has held it in 24 quarters since. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • UBS Group held 1,812,203 shares of Royalty Pharma worth $86.9M as of Q1 2026.
  • UBS Group sold 193,628 Royalty Pharma shares in Q1 2026, an estimated $8.48M.
  • Royalty Pharma made up 0.01% of UBS Group's portfolio in Q1 2026, its #1158 holding.
  • UBS Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 24 quarters since.
  • 588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.